Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide
Humanistic burden and health-related quality of life
7 evidence topics · 7 sources
Patient-reported impact on daily life: multinational survey
“A total of 221 patients with mCRPC and 159 caregivers from USA, France, Germany, Canada, Spain, China, and Brazil were surveyed. mCRPC impacts mood, emotional and mental health (50–77%), sleep (48–68%), career goals (48–80%), and social activities (46–65%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients face high treatment and pill burden (7–12 pills/day) and prefer simpler treatment regimens.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For many patients (52% to 73%), ≥9 hours per week were devoted to mCRPC care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One in three patients experiences fatigue, which is persistent and happens during day-to-day activities (Figure 2(b)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world deterioration of health-related quality of life and pain
“In total, 151 included patients answered 873 questionnaires.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At inclusion, generic HRQoL was high with a mean EQ visual analog score of 73.2 out of 100. The lowest scores were reported on role and physical functioning (mean scores of 69 and 76 of 100, respectively), and fatigue, pain, and insomnia were the most impaired domains. These domains deteriorated in > 50% of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“mCRPC has a negative impact on HRQoL with deterioration in all domains over time, especially role and physical functioning.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health state utility values by disease state
“Data were collected from a total sample of 163 men with metastatic CRPC. Utility values elicited by the EQ-5D-5L ranged from 0.830 for the asymptomatic/mildly symptomatic before chemotherapy disease state (95% confidence interval [CI] 0.795-0.865) to 0.625 for the symptomatic before chemotherapy disease state (95% CI 0.577-0.673).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“EORTC-8D utilities ranged from 0.856 (95% CI 0.831-0.882) to 0.697 (95% CI 0.664-0.731) for the same disease/treatment states.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pooled health state utility values by line of therapy: meta-analysis
“In primary studies, baseline EQ-5D index utility values ranged from 0.7 to 0.9 in 1L and 0.63 to 0.7 in 2L+.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled mean baseline EQ-5D index utility value was estimated as 0.79 (95% CI, 0.70–0.84) and 0.69 (95% CI, 0.67–0.71) for 1L (n = 7 studies) and 2L + (n = 4 studies), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled mean baseline EQ VAS score was estimated as 74.63 (95% CI, 70.97–78.29) and 65.82 (95% CI, 64.53–67.11) in 1L and 2L+, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Time to worsening after progression on one androgen receptor pathway inhibitor
“Eligible patients had metastatic castration-resistant prostate cancer, were candidates for ARPI change after one progression on a previous ARPI” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the [177Lu]Lu-PSMA-617 versus ARPI change groups, median time to worsening in FACT-P total score was 7·46 months (95% CI 6·08-8·54) versus 4·27 months (3·45-4·50; hazard ratio [HR] 0·61 [95% CI 0·50-0·75]), in EQ-5D-5L utility score was 6·28 months (4·70-7·89) versus 3·88 months (3·25-4·44; 0·67 [0·54-0·82]), and in BPI-SF pain intensity was 5·03 months (4·40-6·80) versus 3·65 months (3·09-4·37; 0·72 [0·59-0·88]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“median time to first symptomatic skeletal event was not reached (95% CI not estimable [NE]-NE) in the [177Lu]Lu-PSMA-617 group versus 17·97 months (14·26-NE) in the ARPI change group (HR 0·41 [0·26-0·63]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pain progression with a second androgen receptor pathway inhibitor after docetaxel
“Pain response was observed in 51 (46%) of 111 patients with cabazitaxel and 21 (19%) of 109 patients with abiraterone or enzalutamide (p<0·0001). Median time to pain progression was not estimable (NE; 95% CI NE-NE) with cabazitaxel and 8·5 months (4·9-NE) with abiraterone or enzalutamide (hazard ratio [HR] 0·55, 95% CI 0·32-0·97; log-rank p=0·035).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median time to FACT-P total score deterioration was 14·8 months (95% CI 6·3-NE) with cabazitaxel and 8·9 months (6·3-NE) with abiraterone or enzalutamide (HR 0·72, 95% CI 0·44-1·20; log-rank p=0·21).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pain, skeletal events, and health-related quality of life after taxane and androgen receptor pathway inhibitor
“Pain in patients with mCRPC can be attributed largely to bone metastases, lumbosacral invasion, and nerve root compression, and is associated with shortened OS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Time to worsening was delayed in the 177Lu-PSMA-617 plus SoC group (n = 385) versus SoC alone (n = 196) for FACT-P total score (HR, 0·46; 95% CI: 0·35, 0·61) and subdomains, BPI-SF pain intensity score (HR, 0·45; 95% CI: 0·33, 0·60) and EQ-5D-5L utility score (HR, 0·49; 95% CI: 0·40, 0·62).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SSEs occurred in 60/385 patients (16%) in the 177Lu-PSMA-617 group and 34/196 patients (17%) in the control group (table 2). The predominant types of SSE were radiation to relieve bone pain, followed by spinal cord compression (table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote